OncoMatch/Clinical Trials/NCT05678270
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Is NCT05678270 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ICP-192 for intrahepatic cholangiocarcinoma (icc).
Treatment: ICP-192 — This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: FGFR2 fusion/rearrangement
FGFR2 fusion /rearrangement as confirmed by the central laboratory
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
tumor that has progressed following at least one line of chemotherapy
Cannot have received: FGFR inhibitor
Prior treatment with selective FGFR inhibitors or FGFR antibodies
Lab requirements
Blood counts
Organ functions meeting the protocol requirements
Kidney function
Organ functions meeting the protocol requirements
Liver function
Organ functions meeting the protocol requirements
Organ functions meeting the protocol requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05678270 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FGFR inhibitor disqualifies patients from enrollment.
Does this trial require FGFR2?
Yes, FGFR2 fusion/rearrangement is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages